<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29016" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sickle Cell Nephropathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aeddula</surname>
            <given-names>Narothama R.</given-names>
          </name>
          <aff>Deaconess HS, IN University School Med</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bardhan</surname>
            <given-names>Mainak</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Baradhi</surname>
            <given-names>Krishna M.</given-names>
          </name>
          <aff>University of Oklahoma</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Narothama Aeddula declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mainak Bardhan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Krishna Baradhi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>9</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29016.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Sickle cell disease (SCD), is an autosomal recessive hemoglobin disorder that results from the replacement of glutamate for valine at the sixth amino acid of the beta-globin chain. This replacement results in the formation of hemoglobin S (HbS) tetramers that accumulate during oxidative stress, tissue hypoxia, or dehydration. The consequence of this is red blood cell sickling, early destruction of erythrocytes, and widespread vaso-occlusive episodes (VOC), subsequently causing multiorgan damage. Sickle cell nephropathy (SCN) is a group of renal complications that include hematuria, proteinuria, hyposthenuria, renal papillary necrosis, renal tubular disorders, acute and chronic kidney injury, sickle cell glomerulopathy, and renal medullary carcinoma. This activity illustrates the evaluation and treatment of sickle cell nephropathy and explains the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe sickle cell disease.</p></list-item><list-item><p>Describe the complications expected in sickle cell nephropathy.</p></list-item><list-item><p>Outline the evaluation and treatment options available for a patient with sickle cell nephropathy.</p></list-item><list-item><p>Outline the importance of improving care coordination among the interprofessional team to monitor the patient for progression to end-stage renal disease and provide early intervention, which can lead to better life expectancy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29016&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29016">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29016.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Sickle cell disease (SCD),&#x000a0;first discovered in West Africa&#x000a0;is an autosomal recessive hemoglobin disorder,&#x000a0;predominantly affecting persons of African, Mediterranean, Indian, and Middle Eastern descent. It&#x000a0;results from the replacement of glutamate for valine at the sixth amino acid of the beta-globin chain.&#x000a0;The&#x000a0;mutation results in hemoglobin S (HbS) tetramers that accumulate during tissue hypoxia, oxidative stress or dehydration. The accumulation leads to red blood cell sickling, early destruction of erythrocytes, and widespread vaso-occlusive episodes (VOC), subsequently resulting in multiorgan damage. Some of the renal complications, collectively known as sickle cell nephropathy (SCN), include hematuria, hyposthenuria,&#x000a0;renal papillary necrosis, proteinuria, renal tubular disorders, acute and chronic kidney injury, sickle cell glomerulopathy, and renal medullary carcinoma.&#x000a0;Clinically significant renal involvement occurs more frequently in sickle cell disease than in sickle cell trait or in combined hemoglobinopathies,&#x000a0;except renal medullary carcinoma, which appears to be more common among sickle cell trait patients.&#x000a0;<xref ref-type="bibr" rid="article-29016.r1">[1]</xref></p>
        <p>Natural history of SCD is highly variable with reduced life expectancy with multiorgan damage in symptomatic patients. In general, all patients have a reduced lifespan. Median survival in the United States and Jamaica is 45 to 55 years.&#x000a0;<xref ref-type="bibr" rid="article-29016.r2">[2]</xref></p>
        <p>Natural history by&#x000a0;age in SCD is&#x000a0;as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Newborn babies are asymptomatic for an initial couple of months, given fetal Hb (HbF) predominance.</p>
          </list-item>
          <list-item>
            <p>Early childhood is characterized by episodes of dactylitis, acute&#x000a0;chest syndrome (ACS), sepsis, splenic sequestration, and stroke. Human parvovirus B19 infection can lead to severe and sudden anemia in children and adolescents with SCD as the virus destroys precursors of the red blood cells.</p>
          </list-item>
          <list-item>
            <p>After age 5: Classic painful vaso-occlusive crisis (VOC), which increases in frequency with age</p>
          </list-item>
          <list-item>
            <p>Adolescence is associated with nocturnal enuresis, avascular necrosis of the hip, leg ulcerations, delayed puberty, and priapism.<xref ref-type="bibr" rid="article-29016.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>After&#x000a0;age 25 to 30, the frequency of VOC tends to reduce and is replaced with signs and symptoms of chronic organ damage, including heart failure, pulmonary hypertension, sickle hepatopathy, and sickle cell nephropathy (SCN).<xref ref-type="bibr" rid="article-29016.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>The primary cause of death in younger patients is usually infection; whereas, in older patients, the primary cause of death is mostly irreversible organ damage.<xref ref-type="bibr" rid="article-29016.r3">[3]</xref></p>
      </sec>
      <sec id="article-29016.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The sickle hemoglobin mutation (hemoglobin S or HbS) results in the replacement of the glutamate for valine in the sixth amino acid position of the beta-globin chain, thereby&#x000a0;changing the arrangement of the Hb tetramer molecule in the homozygous person from A2B2 to A2BS2. SCD occurs in those homozygous for HbS (referred to as sickle cell anemia) or in heterozygotes when HbS coexists with another abnormal or missing beta-chain, for example, HbC (A2SC) or HbS beta thalassemia (A2SBthal). Sickle cell trait occurs in those heterozygous for HbS when the other Hb molecule is normal HbAS (A2SB).&#x000a0;<xref ref-type="bibr" rid="article-29016.r4">[4]</xref>,<xref ref-type="bibr" rid="article-29016.r2">[2]</xref></p>
        <p>Some of the risk factors associated with progression of chronic kidney disease (CKD) in SCN include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Genetic variants of&#x000a0;MYH9&#x000a0;and&#x000a0;APOL1</p>
          </list-item>
          <list-item>
            <p>Infection with parvovirus B19</p>
          </list-item>
          <list-item>
            <p>Recurrent Acute chest syndrome</p>
          </list-item>
          <list-item>
            <p>Vaso occlusive episodes</p>
          </list-item>
          <list-item>
            <p>Nephrotic range proteinuria</p>
          </list-item>
          <list-item>
            <p>Underlying hypertension</p>
          </list-item>
          <list-item>
            <p>Severe anemia</p>
          </list-item>
        </list>
        <p>Coinheritance with alpha-thalassemia apart from higher fetal hemoglobin is protective factors.</p>
      </sec>
      <sec id="article-29016.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The high prevalence of SCD in West Africa and parts of Asia represents a probable survival advantage because the presence of&#x000a0;the sickle cell gene protects against malaria. SCD is now a worldwide health problem because the carrier state has spread throughout Africa, Mediterranean, Middle East and South Asia, the Caribbean, North America, and Northern Europe.<xref ref-type="bibr" rid="article-29016.r5">[5]</xref>&#x000a0;SCD affects anywhere from 70,000 to 100,000 people in the United States and&#x000a0;accounts for less than 1% of all new cases of end-stage renal disease (ESRD).<xref ref-type="bibr" rid="article-29016.r6">[6]</xref>&#x000a0;In a 25-year observational study of 725 SCD patients, 4%&#x000a0;developed&#x000a0;CKD at a median age of 23 years, most of&#x000a0;them requiring dialysis within a few years.<xref ref-type="bibr" rid="article-29016.r7">[7]</xref>&#x000a0;When the study was extended by 15 years, the incidence&#x000a0;was 12% (median age of 37 years).<xref ref-type="bibr" rid="article-29016.r3">[3]</xref> Proteinuria&#x000a0;is common in SCD, occurring in about 30% of patients.&#x000a0;Sickle cell gene prevalence is about 8% in African Americans and about 25% in adult Nigerians.<xref ref-type="bibr" rid="article-29016.r5">[5]</xref></p>
      </sec>
      <sec id="article-29016.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>HbS polymerization is the key pathophysiological event, and it occurs during cellular or tissue hypoxia, oxidative stress, or dehydration. The mutated beta-globin chains of the HbS molecule tend to&#x000a0;form a tetramer resulting in the change in the shape of red blood cell (RBC) to a crescent or sickle,&#x000a0;with increased rigidity.&#x000a0;Local oxygen tension, acidosis, and hyperosmolarity are some&#x000a0;factors that influence the tetramerization. Repeated cycles of tetramer formation make the sickle RBCs exhibit high adhesion to the activated endothelium resulting in increased microvascular transit time, leading to further sickling. The whole process ultimately results in the early destruction of the RBCs and frequent, widespread vaso-occlusive episodes with consequent acute and chronic organ damage.</p>
        <p>The main cause of disease severity is the rate and degree of HbS tetramerization, which leads to 2 major pathophysiologic events:</p>
        <list list-type="bullet">
          <list-item>
            <p>Vaso-occlusion with ischemia-reperfusion injury&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hemolytic anemia<xref ref-type="bibr" rid="article-29016.r8">[8]</xref>,<xref ref-type="bibr" rid="article-29016.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>The renal complications in sickle cell disease originate from the occluded vessels (vasa recta) in the renal medulla, given the low partial pressure of oxygen (10 to 35 mm Hg), acidosis, and high osmolarity, which predisposes to hemoglobin S tetramerization and subsequent sickling of the erythrocytes. Repeated cycles of sickling and sludging lead to microinfarcts and ischemic injury giving rise to chronic microvascular disease which is seen in patients with SCN.<xref ref-type="bibr" rid="article-29016.r10">[10]</xref>&#x000a0;The factors which promote the cycles of chronic medullary hypoxia include<xref ref-type="bibr" rid="article-29016.r11">[11]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypoxia-inducible factor 1alpha (HIF1A) and its activation</p>
          </list-item>
          <list-item>
            <p>Expression of endothelin-1 &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Reduced nitric oxide promoting increased reactive oxygen species and vasoconstriction</p>
          </list-item>
        </list>
        <p>Hyperfiltration injury from a paradoxical increase in the total RBF and GFR in renal medulla ultimately results in proteinuria and glomerulosclerosis, which together with tubulointerstitial fibrosis leads to progressive CKD,<xref ref-type="bibr" rid="article-29016.r12">[12]</xref>. Polyuria, from the decreased concentrating ability, a consequence of tubular injury may be seen in childhood and adolescence. Type IV RTA (hyperkalemia and mild hyperchloremic metabolic acidosis) can be observed in these patients before a significant loss of nephron mass and proteinuria from secondary FSGS (focal segmental glomerulosclerosis). Papillary necrosis may result from ischemia from the sickling of red cells and manifest with gross hematuria and ureteric obstruction from sloughed ischemic papillae.</p>
        <p>Possible mechanisms for glomerular abnormalities in HbSS patients include:</p>
        <list list-type="bullet">
          <list-item>
            <p>The fragmented RBCs in glomerular capillaries activate the mesangial cells, which promote matrix proteins synthesis and migration into the peripheral capillary wall, resulting in GBM reduplication<xref ref-type="bibr" rid="article-29016.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Glomerular deposition of immune complexes comprising renal tubular epithelial antigen and specific antibody to renal tubular epithelial antigen, which mediate the glomerulonephritis<xref ref-type="bibr" rid="article-29016.r14">[14]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29016.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>No pathognomonic lesion defines SCN, but glomerular hypertrophy, leading to hyperfiltration, is universal and is seen in children as young as 1 to 3 years of age.<xref ref-type="bibr" rid="article-29016.r15">[15]</xref>&#x000a0;Given the glomerular hypertrophy, the GFR continues to rise throughout childhood and early adulthood, often exceeding 200 ml/min/1.73 m, but in comparison to diabetic nephropathy, the hyperfiltration is not associated with hypertension, as patients with SCN have lower systemic vascular resistance.<xref ref-type="bibr" rid="article-29016.r16">[16]</xref>&#x000a0;Nephrotic syndrome, though uncommon (up to 4% of patients with proteinuria) is associated with a very poor renal prognosis. An infection with human parvovirus B19 (HPV B19), is a rare cause of acute nephrotic syndrome with severe hemolysis and life-threatening anemia. The biopsy in such patients shows collapsing variant of focal segmental glomerulosclerosis (FSGS).<xref ref-type="bibr" rid="article-29016.r17">[17]</xref>&#x000a0;Renal papillary necrosis can be seen with complete occlusion of vasa recta and can be complicated by superimposed infection and colic from clots.<xref ref-type="bibr" rid="article-29016.r18">[18]</xref>&#x000a0;An aggressive form of renal cell carcinoma, renal medullary carcinoma affects patients with sickle cell hemoglobinopathies, more so in teenagers and young adults. Chronic medullary hypoxia is thought to contribute to its pathogenesis.<xref ref-type="bibr" rid="article-29016.r19">[19]</xref>.&#x000a0;Patients with SCN advance through stages of tubular dysfunction and hyperfiltration, microalbuminuria through heavy proteinuria, and ultimately loss of GFR. Single-nephron GFR increases with the loss of other nephrons, leading to progressive damage to the glomeruli and on renal pathology, it is manifested as FSGS and interstitial fibrosis and tubular atrophy. FSGS is the most common lesion in SCN and is associated with proteinuria. Collapsing&#x000a0;pattern and expansive pattern of FSGS may be observed.<xref ref-type="bibr" rid="article-29016.r20">[20]</xref>&#x000a0;Other renal biopsy lesions that have been reported in SCD comprise thrombotic microangiopathy and membranoproliferative glomerulonephritis, though neither are limited to SCN. The only characteristic interstitial lesion is abundant hemosiderin granules in proximal tubular epithelial cells.<xref ref-type="bibr" rid="article-29016.r21">[21]</xref></p>
      </sec>
      <sec id="article-29016.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Some of the common findings in patients with sickle cell nephropathy include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyperfiltration from glomerular hypertrophy with eGFR exceeding more than 200 ml/minute/1.73 mt2. Hyperfiltration is seen in 51% of patients with HbSS with contribution from hemolysis mediated vasculopathy<xref ref-type="bibr" rid="article-29016.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Self-limiting microhematuria, which can be painless to visible, painful gross hematuria, requiring transfusions.</p>
          </list-item>
          <list-item>
            <p>Microalbuminuria and proteinuria which increases with age, reaching more than 60% of patients with SCD by age 45 years<xref ref-type="bibr" rid="article-29016.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Nephrotic syndrome in up to 4% of patients</p>
          </list-item>
          <list-item>
            <p>Hyposthenuria is almost universal in SCD</p>
          </list-item>
          <list-item>
            <p>Renal infarction presenting with flank or abdominal pain, nausea, vomiting, and fevers</p>
          </list-item>
          <list-item>
            <p>Hyperkalemia and mild hyperchloremic metabolic acidosis (type IV renal tubular acidosis)</p>
          </list-item>
          <list-item>
            <p>Urinary tract infections and pyelonephritis</p>
          </list-item>
          <list-item>
            <p>Nephrogenic diabetes insipidus</p>
          </list-item>
          <list-item>
            <p>Acute kidney injury</p>
          </list-item>
          <list-item>
            <p>Progressive chronic kidney disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29016.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The initial diagnosis is based on the clinical&#x000a0;manifestations and is primarily is a diagnosis of exclusion.&#x000a0;</p>
        <p>The initial investigations in a patient with SCD, who presents with hematuria or proteinuria include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Basic metabolic panel</p>
          </list-item>
          <list-item>
            <p>Urine analysis and urine microalbumin to creatinine ratio</p>
          </list-item>
          <list-item>
            <p>Renal imaging with a renal ultrasound</p>
          </list-item>
          <list-item>
            <p>Intravenous pyelogram for papillary necrosis.</p>
          </list-item>
          <list-item>
            <p>CT scan to rule out medullary renal carcinoma especially in sickle cell trait patients.</p>
          </list-item>
          <list-item>
            <p>Serum albumin levels</p>
          </list-item>
          <list-item>
            <p>Autoantibodies and complement levels</p>
          </list-item>
          <list-item>
            <p>HIV, hepatitis B, and hepatitis&#x000a0;C serologies</p>
          </list-item>
          <list-item>
            <p>Serum electrophoresis</p>
          </list-item>
          <list-item>
            <p>Renal biopsy when clinically&#x000a0;indicated</p>
          </list-item>
          <list-item>
            <p>Review of the current and previous medication history</p>
          </list-item>
        </list>
        <p>In a patient with eGFR less than 60 ml/mt/1.73mt2 with a rapid decline in eGFR by greater than 5mls/mt/1.73mt2 or with persistent proteinuria needs a nephrologist referral and evaluation. Especially, SCD patients with urinary protein to creatinine ratio (UPCR) greater than 300 mg/gm should be evaluated for other causes of CKD.</p>
      </sec>
      <sec id="article-29016.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The conservative approach, with bed rest, oral hydration, remains the cornerstone in the management gross hematuria.</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe cases of hematuria need urine alkalinization, loop diuretics to increase urine flow, and blood transfusion.</p>
          </list-item>
          <list-item>
            <p>Hydroxycarbamide or hydroxyurea is the only proven drug for the management of SCD. It acts primarily by increasing the levels of HbF diluting the levels of HbS and reduce the risk of tetramerization. No randomized adult trial is available, but it is proven to help with hyperfiltration and microalbuminuria in observational studies in children and adolescents and should be considered in patients with early signs of renal disease.</p>
          </list-item>
          <list-item>
            <p>Though a recent systematic review has concluded that available evidence is not sufficient to conclude use of renin-angiotensin system (RAS) blockade in SCN<xref ref-type="bibr" rid="article-29016.r24">[24]</xref>,&#x000a0;it is a well-recognized practice based on its effects on the other proteinuric kidney diseases to initiate the RAS blockade, when the UPCR is greater than 300 mg/gms. Caution is warranted as many patients with SCN has normal or low normal blood pressures and "sick day" instructions to hold the medications during acute illness should be given.</p>
          </list-item>
          <list-item>
            <p>In patients with hypertension, the goal of a patient with proteinuria is less than 130/80 mm Hg.</p>
          </list-item>
          <list-item>
            <p>Evidence on chronic transfusions is mixed with one retrospective analysis showed protection against the development of microalbuminuria in children younger than&#x000a0;9 years of&#x000a0;age. Prolonged courses of transfusions can lead to iron overload which poses challenges to treating clinicians.</p>
          </list-item>
          <list-item>
            <p>Erythropoiesis-stimulating agents (ESA), can be useful in combination with hydroxyurea. ESA should be commenced when hemoglobin(Hg) drops 10% to 15% below the normal reference range. Hg target should be lower in patients with SCD given the risk of vaso-occlusive episodes.</p>
          </list-item>
          <list-item>
            <p>Hg goal for patients with&#x000a0;SCN is recommended to be no more than 10 to 10.5 g/dL, and the rate of correction rate of the anemia is less than 1% to 2% per week, given&#x000a0;the risk of precipitating&#x000a0;a vaso-occlusive crisis.</p>
          </list-item>
          <list-item>
            <p>Intermittent intravenous iron supplementation might be warranted given prolonged subclinical gastrointestinal bleeding.</p>
          </list-item>
          <list-item>
            <p>Aminocaproic acid, which inhibits fibrinolysis by inhibiting plasmin activity, or desmopressin acetate which improves clotting via the increase in plasma factor VIII and von Willebrand factor, can be used in patients with gross hematuria from papillary necrosis.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>High dose urea (up to&#x000a0;160 gm per day) can be used in patients with refractory cases as its shown&#x000a0;to prevent the tetramerization of sickle hemoglobin.</p>
          </list-item>
          <list-item>
            <p>Hemopoietic stem cell transplantation (HSCT) is potentially curative and is largely limited to children who remain resistant to hydroxyurea and with severe cerebrovascular complications, VOC episodes, and acute chest syndrome.</p>
          </list-item>
          <list-item>
            <p>Renal transplantation offers the best survival outcomes in patients with SCN who require renal replacement therapy.<xref ref-type="bibr" rid="article-29016.r25">[25]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29016.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Lupus nephritis</p>
          </list-item>
          <list-item>
            <p>Various glomerulonephritis</p>
          </list-item>
          <list-item>
            <p>Multiple myelomas</p>
          </list-item>
          <list-item>
            <p>Renal cell carcinoma</p>
          </list-item>
          <list-item>
            <p>Nephrolithiasis</p>
          </list-item>
          <list-item>
            <p>Viral nephropathy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29016.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <list list-type="bullet">
          <list-item>
            <p>SCN accounts for less than 1% of ESRD patients in the United States, with higher mortality compared to other causes of ESRD<xref ref-type="bibr" rid="article-29016.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Median survival among patients with and without kidney failure is 29 and 51 years, respectively.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In a US study, the average age of patients with SCN, who reached end-stage renal disease (ESRD) requiring dialysis, is 23.1 years (with HbSS), with a mean time of death from the beginning of dialysis being 4 years.<xref ref-type="bibr" rid="article-29016.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>United States renal data system (1992 through 1997) showed that SCN is an independent risk factor for the death in hemodialysis patients and are less likely to receive a renal transplant.<xref ref-type="bibr" rid="article-29016.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>A French study of dialysis patients with ESRD from SCN compared the five years mortality, with patients of ESRD from other causes and it was 46.3% versus 6.4%. Moreover, these patients were much less likely to receive a renal transplant (26% versus 53.5%).<xref ref-type="bibr" rid="article-29016.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Recurrence of SCN has been reported in the literature.<xref ref-type="bibr" rid="article-29016.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>The latest literature points toward improved outcomes in SN transplant recipients when compared to diabetic kidney disease.<xref ref-type="bibr" rid="article-29016.r28">[28]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29016.s12" sec-type="Consultations">
        <title>Consultations</title>
        <list list-type="bullet">
          <list-item>
            <p>Nephrology</p>
          </list-item>
          <list-item>
            <p>Hematology</p>
          </list-item>
          <list-item>
            <p>Urology</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29016.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>The major underlying pathophysiological mechanism in kidney injury in SCN is from hypoxia,&#x000a0;ischemia, and hemolysis.</p>
          </list-item>
          <list-item>
            <p>Early detection is key as the goal of treatment is to delay the progression of renal failure.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>CKD development is from early glomerular hypertrophy and hyperfiltration; tubular hyperfunctioning; endothelial injury with sickling and vaso-occlusive episodes</p>
          </list-item>
          <list-item>
            <p>Diagnosis of SCN is primarily based on clinical manifestations and is&#x000a0;essentially&#x000a0;a diagnosis of exclusion.</p>
          </list-item>
          <list-item>
            <p>FSGS is the most common glomerular disorder in SCN.</p>
          </list-item>
          <list-item>
            <p>Hydroxyurea should be used in all patients with SCD and RAS blockade should be considered in SCN patients with proteinuria.</p>
          </list-item>
          <list-item>
            <p>Renal manifestations are generally&#x000a0;more common and severe in SCD compared with those seen in sickle cell trait, except medullary renal cell carcinoma.</p>
          </list-item>
          <list-item>
            <p>All forms of renal replacement therapy&#x000a0;are beneficial in ESRD patients from SCN, with renal transplantation giving a demonstrated advantage in survival benefit</p>
          </list-item>
          <list-item>
            <p>Physicians should be vigilant in SCD patients for&#x000a0;any early signs&#x000a0;of renal complications.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29016.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with sickle cell are commonly followed by the primary care provider, nurse practitioner, hematologist and the internist. The renal function in these patients needs to be monitored by an interprofessional team because it can lead to end-stage renal disease and a shortened life expectancy. As soon as the renal function starts to decline, a nephrology consult should be made. Many of these patients do require dialysis and some may benefit from a kidney transplant. Without any treatment, the life span is severely limited.<xref ref-type="bibr" rid="article-29016.r29">[29]</xref></p>
      </sec>
      <sec id="article-29016.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29016&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29016">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/sickle-cell-nephropathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29016">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29016/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29016">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29016.s16">
        <title>References</title>
        <ref id="article-29016.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powars</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Hiti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramicone</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors.</article-title>
            <source>Am J Hematol</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>206</fpage>
            <page-range>206-15</page-range>
            <pub-id pub-id-type="pmid">12111766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serjeant</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>The natural history of sickle cell disease.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2013</year>
            <month>Oct</month>
            <day>01</day>
            <volume>3</volume>
            <issue>10</issue>
            <fpage>a011783</fpage>
            <pub-id pub-id-type="pmid">23813607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powars</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Hiti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramicone</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>84</volume>
            <issue>6</issue>
            <fpage>363</fpage>
            <page-range>363-376</page-range>
            <pub-id pub-id-type="pmid">16267411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hockham</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Piel</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Penman</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Understanding the contrasting spatial haplotype patterns of malaria-protective &#x003b2;-globin polymorphisms.</article-title>
            <source>Infect Genet Evol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>36</volume>
            <fpage>174</fpage>
            <page-range>174-183</page-range>
            <pub-id pub-id-type="pmid">26394108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piel</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Tatem</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Weatherall</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000.</article-title>
            <source>Lancet Glob Health</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>e80</fpage>
            <page-range>e80-9</page-range>
            <pub-id pub-id-type="pmid">24748392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abbott</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Hypolite</surname>
                <given-names>IO</given-names>
              </name>
              <name>
                <surname>Agodoa</surname>
                <given-names>LY</given-names>
              </name>
            </person-group>
            <article-title>Sickle cell nephropathy at end-stage renal disease in the United States: patient characteristics and survival.</article-title>
            <source>Clin Nephrol</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-15</page-range>
            <pub-id pub-id-type="pmid">12141416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powars</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Elliott-Mills</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Niland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hiti</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Opas</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality.</article-title>
            <source>Ann Intern Med</source>
            <year>1991</year>
            <month>Oct</month>
            <day>15</day>
            <volume>115</volume>
            <issue>8</issue>
            <fpage>614</fpage>
            <page-range>614-20</page-range>
            <pub-id pub-id-type="pmid">1892333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akinsheye</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Solovieff</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ngo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Malek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sebastiani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Chui</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Fetal hemoglobin in sickle cell anemia: molecular characterization of the unusually high fetal hemoglobin phenotype in African Americans.</article-title>
            <source>Am J Hematol</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>87</volume>
            <issue>2</issue>
            <fpage>217</fpage>
            <page-range>217-9</page-range>
            <pub-id pub-id-type="pmid">22139998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rees</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Gladwin</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Sickle-cell disease.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Dec</month>
            <day>11</day>
            <volume>376</volume>
            <issue>9757</issue>
            <fpage>2018</fpage>
            <page-range>2018-31</page-range>
            <pub-id pub-id-type="pmid">21131035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Statius van Eps</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Pinedo-Veels</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>de Koning</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Nature of concentrating defect in sickle-cell nephropathy. Microradioangiographic studies.</article-title>
            <source>Lancet</source>
            <year>1970</year>
            <month>Feb</month>
            <day>28</day>
            <volume>1</volume>
            <issue>7644</issue>
            <fpage>450</fpage>
            <page-range>450-2</page-range>
            <pub-id pub-id-type="pmid">4189754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurbanov</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rubinstein</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abassi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Better</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Winaver</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Differential regulation of renal regional blood flow by endothelin-1.</article-title>
            <source>Am J Physiol</source>
            <year>1996</year>
            <month>Dec</month>
            <volume>271</volume>
            <issue>6 Pt 2</issue>
            <fpage>F1166</fpage>
            <page-range>F1166-72</page-range>
            <pub-id pub-id-type="pmid">8997390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheinman</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Sickle cell disease and the kidney.</article-title>
            <source>Nat Clin Pract Nephrol</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>78</fpage>
            <page-range>78-88</page-range>
            <pub-id pub-id-type="pmid">19048000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elfenbein</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Patchefsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Pathology of the glomerulus in sickle cell anemia with and without nephrotic syndrome.</article-title>
            <source>Am J Pathol</source>
            <year>1974</year>
            <month>Dec</month>
            <volume>77</volume>
            <issue>3</issue>
            <fpage>357</fpage>
            <page-range>357-74</page-range>
            <pub-id pub-id-type="pmid">4611224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pardo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ozawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McIntosh</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Nephropathy associated with sickle cell anemia: an autologous immune complex nephritis. II. Clinicopathologic study of seven patients.</article-title>
            <source>Am J Med</source>
            <year>1975</year>
            <month>Nov</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>650</fpage>
            <page-range>650-9</page-range>
            <pub-id pub-id-type="pmid">128292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aygun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mortier</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Smeltzer</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Hankins</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Glomerular hyperfiltration and albuminuria in children with sickle cell anemia.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>8</issue>
            <fpage>1285</fpage>
            <page-range>1285-90</page-range>
            <pub-id pub-id-type="pmid">21559933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pegelow</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Colangelo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vichinsky</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia.</article-title>
            <source>Am J Med</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>102</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-7</page-range>
            <pub-id pub-id-type="pmid">9217567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sharpe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dutt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Height</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Allman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Awogbade</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Zuckerman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thein</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Acute human parvovirus B19 infection and nephrotic syndrome in patients with sickle cell disease.</article-title>
            <source>Br J Haematol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>149</volume>
            <issue>2</issue>
            <fpage>289</fpage>
            <page-range>289-91</page-range>
            <pub-id pub-id-type="pmid">20064150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharpe</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Thein</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Sickle cell nephropathy - a practical approach.</article-title>
            <source>Br J Haematol</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>155</volume>
            <issue>3</issue>
            <fpage>287</fpage>
            <page-range>287-97</page-range>
            <pub-id pub-id-type="pmid">21902687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alvarez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sarnaik</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Renal medullary carcinoma and sickle cell trait: A systematic review.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>62</volume>
            <issue>10</issue>
            <fpage>1694</fpage>
            <page-range>1694-9</page-range>
            <pub-id pub-id-type="pmid">26053587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasr</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Sentman</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>VD</given-names>
              </name>
            </person-group>
            <article-title>Sickle cell disease, nephrotic syndrome, and renal failure.</article-title>
            <source>Kidney Int</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>69</volume>
            <issue>7</issue>
            <fpage>1276</fpage>
            <page-range>1276-80</page-range>
            <pub-id pub-id-type="pmid">16482096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maigne</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferlicot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Galacteros</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Belenfant</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ulinski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Niaudet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ronco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Godeau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Durrbach</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sahali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lambotte</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Audard</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Glomerular lesions in patients with sickle cell disease.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>89</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-27</page-range>
            <pub-id pub-id-type="pmid">20075701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haymann</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Stankovic</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Avellino</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tharaux</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Letavernier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grateau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baud</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Girot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lionnet</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2010</year>
            <month>May</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>756</fpage>
            <page-range>756-61</page-range>
            <pub-id pub-id-type="pmid">20185605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guasch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Navarrete</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nass</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zayas</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Glomerular involvement in adults with sickle cell hemoglobinopathies: Prevalence and clinical correlates of progressive renal failure.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>8</issue>
            <fpage>2228</fpage>
            <page-range>2228-35</page-range>
            <pub-id pub-id-type="pmid">16837635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sasongko</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Nagalla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ballas</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2015</year>
            <month>Jun</month>
            <day>04</day>
            <volume>2015</volume>
            <issue>6</issue>
            <fpage>CD009191</fpage>
            <pub-id pub-id-type="pmid">26041152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saxena</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Panhotra</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Al-Ghamdi</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Should early renal transplantation be deemed necessary among patients with end-stage sickle cell nephropathy who are receiving hemodialytic therapy?</article-title>
            <source>Transplantation</source>
            <year>2004</year>
            <month>Mar</month>
            <day>27</day>
            <volume>77</volume>
            <issue>6</issue>
            <fpage>955</fpage>
            <page-range>955-6</page-range>
            <pub-id pub-id-type="pmid">15077050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nielsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Canou&#x000ef;-Poitrine</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jais</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Dahmane</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bartolucci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bentaarit</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gellen-Dautremer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Remy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kofman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matignon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suberbielle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jacquelinet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wagner-Ballon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sahali</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Damy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Galact&#x000e9;ros</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grimbert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Habibi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Audard</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Morbidity and mortality of sickle cell disease patients starting intermittent haemodialysis: a comparative cohort study with non- Sickle dialysis patients.</article-title>
            <source>Br J Haematol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>174</volume>
            <issue>1</issue>
            <fpage>148</fpage>
            <page-range>148-52</page-range>
            <pub-id pub-id-type="pmid">26992059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tejani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Phadke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Adamson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nicastri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Renal lesions in sickle cell nephropathy in children.</article-title>
            <source>Nephron</source>
            <year>1985</year>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>352</fpage>
            <page-range>352-5</page-range>
            <pub-id pub-id-type="pmid">3982580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Parke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mehrnia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kamgar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Danovitch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bunnapradist</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Improved survival among sickle cell kidney transplant recipients in the recent era.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>1039</fpage>
            <page-range>1039-46</page-range>
            <pub-id pub-id-type="pmid">23345624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29016.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almasri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benkhadra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Farah</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Alvarez Villalobos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Prokop</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kasiske</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Israni</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review for Variables to Be Collected in a Transplant Database for Improving Risk Prediction.</article-title>
            <source>Transplantation</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>103</volume>
            <issue>12</issue>
            <fpage>2591</fpage>
            <page-range>2591-2601</page-range>
            <pub-id pub-id-type="pmid">30768569</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
